DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Sirukumab is an investigational drug.
There have been 11 clinical trials for Sirukumab. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2012.
The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Polymyalgia Rheumatica. The leading clinical trial sponsors are GlaxoSmithKline, Janssen Research & Development, LLC, and Janssen Pharmaceutical K.K.
There are five US patents protecting this investigational drug and forty-four international patents.
Recent Clinical Trials for Sirukumab
|Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica||GlaxoSmithKline||Phase 3|
|A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma||GlaxoSmithKline||Phase 2|
|Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis||GlaxoSmithKline||Phase 3|
Top disease conditions for Sirukumab
Top clinical trial sponsors for Sirukumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Sirukumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Sirukumab||Start Trial||Soluble C5aR antagonists||ChemoCentryx, Inc. (Mountain View, CA)||Start Trial|
|Sirukumab||Start Trial||Cholestosome vesicles for incorporation of molecules into chylomicrons||THERASYN SENSORS, INC. (Eggertsville, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|